According to the FDA's
research, this implant is a good alternative for myopes who were poor candidates for Lasik either because of thin corneae or myopia outside the currently treatable range.
"The approval was based on data from a clinical study (n = 294) showing
that 95% of patients had 20/40 vision or better and 59% had 20/20 vision or
better at 3 years postimplantation."
"The ICL remains our most significant opportunity for profitable growth going forward and receipt of FDA approval represents a critical milestone," said David Bailey, President and CEO of
STAAR Surgical. "Throughout the approval process, doctors' interest in our state-of-the-art lens has continued to build, driven by superior clinical outcomes, the stability and safety of the procedure and the high patient satisfaction rate.
According to the FDA's research, this implant is a good alternative for myopes who were poor candidates for Lasik either because of thin corneae or myopia outside the currently treatable range.
So this appears to be for patients with higher myopia or thinner corneas than we like to do in LASIK patients, and minimal astigmatism.
ReplyDelete